Zynerba Press Releases

19 Oct 21 Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

8 Oct 21 Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

20 Sep 21 Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

13 Sep 21 Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

9 Sep 21 Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

7 Sep 21 Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

2 Sep 21 Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

2 Sep 21 Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

9 Aug 21 Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

4 Aug 21 Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference